BioPhy, CEO & Co-Founder Dave Latshaw II | Founding Philly Ep. 43

Presented by Comcast NBCUniversal LIFT Labs.

--

In this episode, I interview Dave Latshaw II, CEO and Co-Founder of BioPhy, an AI-driven company committed to bringing better drugs and therapies to market faster.

Significant capital is being invested in artificial intelligence for drug discovery, yet traditional drug development remains notoriously slow, inefficient, and risky. This raises a critical question: How is the industry preparing for a future where AI drives faster and more expansive drug discovery pipelines?

As Dave puts it, “The industry as a whole is unprepared for a post-artificial intelligence world in drug discovery. There's no technology platform that comprehensively addresses this challenge. So that's really what we're after—how do you create a tech-enabled development process?”

Dave, originally a biochemical engineer, transitioned from a career at Johnson & Johnson to entrepreneurship, driven by his passion for solving complex problems in the pharmaceutical industry.

Recognizing these inefficiencies, Dave founded BioPhy to integrate AI technologies that enhance the speed and success rate of drug development. BioPhy specifically targets the post-discovery phase, using AI to accelerate drug candidates toward market readiness.

BioPhy has two main platforms:

BioLogicAI—This tool predicts clinical trial outcomes with impressive accuracy, helping companies quickly identify the most promising drug candidates.

BioPhyRx—This AI provides real-time guidance for scientists and regulatory professionals, streamlining everything from compliance checks to operational workflows.

Today, BioPhy's AI-driven platforms are widely adopted by pharmaceutical companies to streamline drug development. These technologies not only speed up the process but also reduce costs, ultimately bringing effective drugs to patients more quickly.

In this podcast episode, Dave shares his journey from engineer to entrepreneur, the challenges and successes of integrating AI into a regulated industry, and his vision for the future of pharmaceuticals with AI.